DE9213939U1 - Pharmazeutische Mischung - Google Patents
Pharmazeutische MischungInfo
- Publication number
- DE9213939U1 DE9213939U1 DE9213939U DE9213939U DE9213939U1 DE 9213939 U1 DE9213939 U1 DE 9213939U1 DE 9213939 U DE9213939 U DE 9213939U DE 9213939 U DE9213939 U DE 9213939U DE 9213939 U1 DE9213939 U1 DE 9213939U1
- Authority
- DE
- Germany
- Prior art keywords
- ingredients
- pharmaceutical mixture
- dose
- pharmaceutical
- med
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims description 5
- 239000002775 capsule Substances 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N quercetin Natural products C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 3
- 235000005875 quercetin Nutrition 0.000 claims description 3
- 229960001285 quercetin Drugs 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- -1 quercetin ester Chemical class 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 229910052712 strontium Inorganic materials 0.000 claims 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 3
- 229960003646 lysine Drugs 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000001925 catabolic effect Effects 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE9213939U DE9213939U1 (de) | 1992-10-15 | 1992-10-15 | Pharmazeutische Mischung |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE9213939U DE9213939U1 (de) | 1992-10-15 | 1992-10-15 | Pharmazeutische Mischung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE9213939U1 true DE9213939U1 (de) | 1993-03-11 |
Family
ID=6884867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE9213939U Expired - Lifetime DE9213939U1 (de) | 1992-10-15 | 1992-10-15 | Pharmazeutische Mischung |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE9213939U1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10101522B4 (de) * | 1997-07-08 | 2007-02-22 | Rath, Matthias, Dr. | Neue pharmazeutische Verwendung einer Kombination aus Ascorbat und mindestens einem Fibrinolysehemmer |
-
1992
- 1992-10-15 DE DE9213939U patent/DE9213939U1/de not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10101522B4 (de) * | 1997-07-08 | 2007-02-22 | Rath, Matthias, Dr. | Neue pharmazeutische Verwendung einer Kombination aus Ascorbat und mindestens einem Fibrinolysehemmer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3787377T2 (de) | Eindringungserhöhende mittel zur transdermalen verabreichung systemischer mittel. | |
| DE3875705T2 (de) | Carbidopa-levodopa-zusammensetzung mit gesteuerter freigabe. | |
| DE726766T1 (de) | Neue pharmazeutische zusammensetzung, die den ace-hemmer ramipril und eine dihydropyridin-verbindung enthält | |
| DE3382616T2 (de) | Vermittler des durchdringungsvermoegens zur transdermalen verabreichung systemischer wirkstoffe. | |
| DE637241T1 (de) | Synergistische kombination einer substanz mit hemmwirkung auf die magensäuresekretion und eines säureinstabilen antibiotikums. | |
| KR0145739B1 (ko) | 발포정 | |
| DE1667888A1 (de) | Langwirkende Tabletten oder Dragees | |
| DE194202T1 (de) | Pharmazeutische zusammensetzung aus guar-gummi und anderen antiacida zum schutzen der oeso-gastro-duodenalen schleimhaut. | |
| DE69532285T2 (de) | Zusammensetzung zur verminderung von schmerzen, die ein nicht narkotisches analgetika und ein analgetikabekräftiger enthält | |
| DE1915798C3 (de) | Antacidum-Präparat in Form einer wäßrigen Suspension | |
| CN1088358C (zh) | 含有镇咳药和苄达明的镇咳组合物 | |
| DE9213939U1 (de) | Pharmazeutische Mischung | |
| DE60013466T2 (de) | Im mund zerfallende zusammensetzung mit mirtazapin | |
| DE3130912A1 (de) | Analgetische arzneimittelkombination | |
| US7138148B2 (en) | Use of extracts of Ginkgo biloba for preparing a medicament intended to treat sarcopenia | |
| DE1935879A1 (de) | Pharmazeutisches Praeparat und Verfahren zur Herstellung von diesem | |
| JPH0358328B2 (fr) | ||
| KR20090125748A (ko) | 대상포진 후 신경통 치료용 정제 및 대상포진 후 신경통의 치료 방법 | |
| KR100298647B1 (ko) | 발모촉진제 및 그의 제조방법 | |
| KR20070065955A (ko) | 마이크로캡슐 내에 기능성 원료를 함유한 치약 | |
| DE2528460A1 (de) | Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans | |
| DE2923955A1 (de) | Pharmazeutisches mittel zur behandlung sexueller frigiditaet und impotenz | |
| DE2705817A1 (de) | Neue anti-hypertonische zubereitungen mit gehalt an phenylhydrazinpropionsaeure und blutdrucksenkendem mittel | |
| CN1051455C (zh) | 烧、烫伤药水及配制方法 | |
| DE3750264T2 (de) | Durchdringungserhöhende mittel für transdermale verabreichung systemischer mittel. |